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INTRODUCTION: An increase in detection of early-stage asymptomatic lung tumors could increase the overall survival
rate of lung cancer patients. A new approach to cancer (pre-)screening focusses on detecting field cancerization
instead of the tumor itself. The objective of this study was to investigate the use of optical spectroscopy to detect
field cancerization in the buccal mucosa of lung cancer patients. METHODS: Optical buccal mucosa measurements
were performed in lung cancer patients and controls using multidiameter single-fiber reflectance spectroscopy. We
analyzed whether the measured optical parameters could distinguish lung cancer patients from controls. RESULTS:
Twenty-three lung cancer patients, 24 chronic obstructive pulmonary disease (COPD) control patients, and 36 non-
COPD controls were included. The majority of tumors were non-small-cell lung carcinomas (96%) and classified as
stage I (48%). The tissue scattering properties ms' and g at 800 nm and the tissue bilirubin concentration were all
near-significantly different (P ¼ .072, 0.058, and 0.060, respectively) between the lung cancer and COPD group. ms'
at 800 nm had a sensitivity of 74% and a specificity of 63%. The microvascular blood oxygen saturation of the lung
cancer patients was also higher than the COPD patients (78% vs. 62%, P ¼ .002), this is probably a consequence of
the systemic effect of COPD. CONCLUSIONS: We have demonstrated that ms' at 800 nm is increased in the buccal
mucosa of patients with lung cancer compared to controls with COPD. This might be an indication of field
cancerization in the oral cavity of patients with lung cancer.
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Lung cancer is a major public health problem because of its high
incidence and high mortality. It is the worldwide leading cause of
cancer related death. [1] This high mortality is partly caused by the
fact that early-stage lung cancer often causes no clinical symptoms. [2]
As a result lung cancer is commonly diagnosed in more advanced
stages of development with regional and distant metastases. [1]
Patients with early-stage lung tumors can benefit from complete
surgical resection or curative radiotherapy, whereas treatment of
patients with high-stage tumors is often not curative. [2] This results
in a substantially higher 5-year survival of 52% for patients with
early-stage tumors than the 5-year survival of 15% of the total lung
cancer population. [1]
Early detection by screening asymptomatic high-risk patients holds
the potential to substantially increase the survival rate of lung cancer
patients. At present, most scientific research has focused on low-dose
computed tomography (LDCT). [3] The largest randomized
controlled trial on the effectiveness of LDCT-screening for lung
cancer showed a 20% lung cancer mortality reduction compared to
using chest radiography. [4] The awaited mortality outcome results of
the DutcheBelgian randomized lung cancer screen trial (NELSON
trial) are thought to replicate this reduction. [5] A recent systematic
review recommended to LDCT-screen adults between 55 and 74
years who are at high risk for lung cancer. [6] However, they also warn
of the potential harm of screening: false-positive results, adverse
effects of invasive follow-up testing, and overdiagnosis.
A novel strategy for lung cancer (pre-)screening is focused on field
cancerization (FC). The goal of this type of screening is not to detect
the tumor itself but instead detect local tissue changes caused by FC.
These superficial tissue changes are caused by accumulating exposure
to carcinogens and include alterations in the microvasculature and the
tissue nanoscale architecture, such as the organization of the
cytoskeleton and the size and structure of cell nuclei and organelles.
[7,8] An alternative theory states that multiple fields arise due to the
migration of dysplastic and altered cells. Either by migration of
malignant cells through the saliva (micro metastasis) or intra-epithe-
lial migration of the progeny of initially transformed malignant cells.
[9,10] The FC of lung cancer is assumed to consist of the entire upper
airway including the main bronchi, trachea and even the, easily
accessible, oral cavity. [11] Most research on FC lung cancer
screening is done on airway tissue gene expression. [3] However, this
is an expensive and time consuming method. Optical reflectance
spectroscopy has been proposed as a fast and easy-to-use alternative
technique to detect FC and possibly use for cancer screening. [7]
The approach to pre-screen for lung cancer has been investigated
by Roy et al. by optical measurements of the buccal mucosa. [12,13]
In a first ex vivo study they showed the proof of concept that buccal
optical spectroscopy may potentially work as a pre-screening tool for
lung cancer. [12] In a second in vivo study an optical fiber was used to
interrogate the buccal mucosa with the aim to detect FC changes.
[13] Their optical biomarker was able to predict the presence of lung
cancer with a sensitivity of 79% and a specificity of 83%. However,
50% of the control patients in the validation set were non-smokers,
which may have influenced the study outcome.
Our research group has developed a novel optical technique:
multidiameter single-fiber reflectance (MDSFR) spectroscopy. [14] It
enables fast, non-invasive measurements of how much light has been
absorbed and scattered in tissue. Spectral deconvolution of the tissue
absorption coefficient yields measurements of four physiologicalthe quantification of two scattering parameters: the reduced scattering
coefficient ms' and the phase function parameter g. These scattering
parameters are closely related to the nanoscale architecture of tissue
and thus to FC changes. In two previous studies, our group used
MDSFR spectroscopy to detect FC in the buccal mucosa of patients
with esophageal and laryngeal cancer. [15,16] These results show the
promise of the use of MDSFR spectroscopy as a cancer pre-screening
tool. In laryngeal cancer patients, the blood oxygen saturation and
blood volume fraction were lowered in the buccal mucosa of the
oncologic patients. [16] The combined parameter a, encompassing
StO2 and BVF, was able to predict the presence of a laryngeal tumor
with a sensitivity of 78% and a specificity of 74%. In esophageal
cancer patients the ms' at 450 and 800 nm was increased in the buccal
mucosa of the oncologic group, indicating changes in the nanoscale
architecture possibly related to FC. [15]
The present study reports the first attempt to use MDSFR
spectroscopy in the buccal mucosa of lung cancer patients to
investigate if FC changes can be detected. This was accomplished by
comparing the buccal mucosa optical properties of patients with and
without lung cancer. We hypothesize that the values of the optical
parameters will be different between these groups. This could indicate
the presence of FC and thus a, distant, lung tumor. If proven feasible,
this technique might be used as a pre-screening tool for a high-risk
population and possible reduce lung cancer mortality by diagnosing
more early-stage tumors.
Materials and Methods
Subjects and Examination Procedure
This prospective study was approved by the Medical Ethics
Committees of the Erasmus MC Cancer Institute (MEC-2015-256)
and the Franciscus Gasthuis& Vlietland. Patients were recruited from
the outpatient clinic of the Pulmonology department of the
Franciscus Gasthuis & Vlietland and the outpatient clinic of the
Thoracic Surgery department of the Erasmus MC Cancer Institute
between November 2016 and February 2018. Clinical parameters
such as: sex, age, medical history, smoking (never/past/current and
pack-years) and TNM-stage of tumor were collected using the
electronic medical record (CSC-iSOFT, Virginia, USA). The
oncologic group of patients consisted of patients with primary and
untreated lung cancer. Patients with non-small cell lung cancer
(NSCLC) and patients with small cell lung cancer (SCLC), tumor
stages (I-IV), were included. The lung tumors were confirmed by
imaging techniques or histopathology. The two non-oncologic
control groups consisted of patients with chronic obstructive
pulmonary disease (COPD) and non-COPD smoking patients with
a variety of other non-oncologic diseases (e.g., chronic rhinosinusitis,
cholesteatoma, gastro-esophageal reflux, dysphagia, and abdominal
pain). The absence of an occult, unexpected malignancy in the lungs
was confirmed by CT imaging <1 year prior to inclusion in the study
in the COPD group. Patients with a medical history of head and neck
or esophageal cancer were excluded from this study. Informed
consent forms were signed before inclusion in this study by all
patients.
The multi diameter single fiber reflectance in vivomeasurements of
the buccal mucosa were performed at the outpatient clinic (Figure 1).
A single investigator (OB) performed all measurements. After
disinfecting the fiber bundle with Tristel Trio (Tristel Solutions
Figure 1. Multidiameter single-fiber reflectance spectroscopy
probe on the buccal mucosa. (A) Overview picture with in the
background spectra on laptop. (B) Detail of probe tip angled at
15 degrees.
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the buccal mucosa. Five consecutive MDSFR measurements were
performed with the probe-tip on the same place on the mucosa. In
total, the measurements take approximately 40 seconds.
Study Samples
Eighty-three patients were included in this study: 23 patients with
lung cancer, 24 control patients with COPD, and 36 non-COPD
control patients (Table 1). The percentage of males was 56.5% in the
lung cancer group, 41.7% in the COPD group (P ¼ .308), and
75.0% in the non-COPD control group (P ¼ .138). The median ageTable 1. Baseline Characteristics of Lung Cancer, COPD Control and Non-COPD Control
Patients
Lung Cancer COPD
Control
P-value Non-COPD
control
P-value
N 23 24 36
Male sex, n (%) 13 (56.5) 10 (41.7) .308 27 (75.0) .138
Age, median (IQR)
69.1
(64.3e73.68)
62.0
(51.8e65.6)
.001*
65.0
(58.3e69.1)
.042*
Smoking, n (%) .555 .266
Never 1 (4.3) 0 (0.0) 0 (0.0)
Past 13 (56.5) 13 (54.2) 26 (72.2)
Current 9 (39.1) 11 (45.8) 10 (27.8)
Smoking PY, median
(IQR)
36.0
(20.0e50.0)
37.5
(25.5e45.8)
.594
30.0
(15.0e49.0)
.539
PY ¼ pack years. P-values calculated with chi-square test (sex and smoking status) and
ManneWhitney U test (age and smoking pack years). *P < .005.of the patients was 69.1 (IQR 64.3e73.7) years in the lung cancer
group. This was higher than the COPD control group (62.0 [IQR
51.8e65.6], P ¼ .001) and the non-COPD control group (65.0
[IQR 58.3e69.1], P ¼ .042). There was no significant difference in
smoking status or smoking pack years between the lung cancer and
both control groups.
Table 2 shows the tumor stage and type of the lung cancer group.
Most tumors were stage I (12, 52.2%). Four tumors were stage II
(17.4%), 4 tumors were stage III (17.4%) and 3 tumors were stage IV
(13.1%). The majority of tumors were NSCLC of which 12 were
squamous cell carcinomas, 8 were adenocarcinomas and 2 were
undifferentiated large cell carcinoma. One patient (4.3%) had a
SCLC.
Multidiameter Single-Fiber Reflectance Device
The buccal mucosa in vivo measurements were performed with a
custom made MDSFR spectroscopy device, which was described in
detail in a previous paper. [14] In summary, MDSFR spectroscopy
uses a bundle of 19 fibers for both light delivery and collection. Each
fiber of 200 mm in the bundle is trifurcated at the proximal end to
enable light delivery from a halogen lamp, light delivery from a 365
nm and 405 nm LED, and light collection to the spectrometer. The
fibers are bundled into three concentric groups of 1, 6 and 12 fibers.
They are polished at an angle of 15 degrees at the fiber tip to avoid
collection of specular reflection. The last 10 cm of the fiber bundle
towards the fiber tip is encased in a 12 mm diameter curved metal
housing, for optimal application on buccal mucosa (Figure 1). Three
computer-controlled shutters and a series of fiber-optic interconnects
enable illumination and spectroscopic detection of independent fiber
groups. This allows single fiber reflectance (SFR) measurement of
200, 600 and 1000 mm without moving the probe. The sampling
diameter (over which parameters are averaged) is 1000 mm. The
sampling depth is of the order of 500 mm (half the maximum fiber
diameter). The MDSFR spectroscopy device is easily portable and has
been approved to be used in the clinic. A detailed description of the
system calibration and validation has been described previously. [14]
The maximal sampling depth of MDSFR spectroscopy is
approximately 500 mm. For the buccal mucosa this seems to be
well matched for the superficial occurrence of FC. The epithelial layer
of the buccal mucosa is 250e350 mm thick and the, vascularized,
lamina propria is 300e350 mm thick. [17,18]
Spectral Analysis
The complete analysis of spectra is described in detail in a previous
paper by our group. [19] First, the tissue absorption properties were
calculated using the individual SFR spectra of the 200, 600, and 1000Table 2. Tumor stage and type of lung cancer group
Tumor stage, n (%)
I 12 (52.2)
II 4 (17.4)
III 4 (17.4)
IV 3 (13.0)
Tumor type, n (%)
NSCLC 22 (95.7)
- Squamous cell carcinoma - 12 (52.2)
- Adenocarcinoma - 8 (34.8)
- Unknown - 2 (8.7)
SCLC 1 (4.3)
NSCLC ¼ non-small cell lung cancer; SCLC ¼ small cell lung cancer.
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1) and g
(), that are influenced by the angular scattering probability (phase
function), were determined by combining the absorption-corrected
spectra of multiple fiber diameters. Finally, four physiological
parameters were extracted from the 1000 mm SFR fit: microvascular
blood oxygen saturation (StO2 [%]), blood volume fraction (BVF
[%]), mean vessel diameter (VD [mm]) and tissue bilirubin
concentration ([BIL]tis [mmol/L]).
Statistical Analysis
The optical parameters were calculated by averaging the five buccal
mucosa measurements taken per patient. Ten parameters were
analyzed: StO2, BVF, VD, [BIL]tis, ms' at 450 and 800 nm, g at 450
and 800 nm, and average g. Our sample size was calculated based on a
study that tried to differentiate lung cancer patients from controls
with ex vivo optical measurements of buccal mucosa cells. The
difference in mean of their optical parameter was 2.3 with a standard
deviation of 1.0. It was hypothesized that standard deviation of our
measurements would be higher (2.1) because they were performed in
a heterogeneous in vivo environment. The number of patients
required in each group would therefore be 23 (power ¼ 0.8 and
alpha ¼ 0.01). Continuous data were reported as median value and
interquartile range (IQR) (non-normally distributed data and n < 30
per group) and differences between two groups were analyzed using a
binary logistic regression, with age at measurement as a covariate.
Categorical data were reported as counts and percentages, and
differences between groups were analyzed using the chi-squared test
or the Fisher's exact test when appropriate. Binary logistic regression
(with age as covariate) was used to investigate if the outcome
parameters were significantly different between the two groups. The
sensitivity and specificity of optical parameters to predict patients
with lung cancer were calculated using an ROC-curve. There were no
missing data. Statistical analysis was performed using SPSS version 21
(IBM Co., Armonk, NY, USA) and the cut off point for significance
was P < .05.
Results
Table 3 presents the results of the buccal mucosa in vivo
measurements of the lung cancer patients and the two control
groups. The StO2 in the buccal mucosa of the lung cancer patients
was 77.5% (IQR 70.8e82.1), which was significantly higher than in
the COPD control group (62.3% [IQR 57.6e68.3], P ¼ .002). The
[BIL]tis, ms' at 800 nm, and g at 800 nm parameters were all
near-significantly different between the lung cancer and COPD
control group. ms' at 800 nm was also significantly lower in theTable 3. Optical properties of buccal mucosa measurements
Parameter Lung cancer COPD control
(Median [IQR]) (n ¼ 23) (n ¼ 24)
StO2 (%) 77.5 (70.8e82.1) 62.3 (57.6e68.3)
BVF (%) 2.50 (1.70e3.30) 2.30 (1.73e3.68)
VD (mm) 0.04 (0.03e0.06) 0.05 (0.04e0.08)
[BIL]tis (mmol/L) 7.30 (4.89e9.88) 9.59 (6.69e11.6)
ms' at 800 nm (mm
1) 1.04 (0.98e1.13) 0.96 (0.90e1.04)
ms' at 450 nm (mm
1) 1.82 (1.61e2.10) 1.84 (1.65e2.11)
g at 800 nm () 1.64 (1.60e1.74) 1.63 (1.57e1.68)
g at 450 nm () 1.65 (1.59e1.72) 1.68 (1.56e1.74)
g average () 1.65 (1.60e1.75) 1.66 (1.60e1.72)
IQR ¼ interquartile range, StO2 ¼ blood oxygen saturation, BVF ¼ blood volume fraction, VD
g ¼ phase function parameter. P values were calculated with binary logistic regression, with age at mnon-COPD control group (1.00 [IQR 0.93e1.05] vs. 1.04 [IQR
0.98e1.13], P ¼ .015). On the other hand, the BVF was higher in
the non-COPD control group (3.25 [IQR 2.73e3.61]) than in the
lung cancer group (2.50 [IQR 1.70e3.30]).
Figure 2 shows the discriminative power of two buccal mucosa
parameters, StO2 and ms' at 800 nm, that differentiate the best
between lung cancer patient and controls. Compared to the COPD
group, StO2 could predict the presence of a lung tumor with a
sensitivity of 78.3%, a specificity of 79.2% and an area under the
curve (AUC) of 86.5% (95% CI 76.1e96.9). ms' at 800 nm had a
lower discriminative power between the same two groups with a
sensitivity of 73.9%, a specificity of 62.5% and an AUC of 69.2%
(95% CI 53.9e84.6). The results of ms' at 800 nm compared to the
non-COPD group were similar with a sensitivity of 65.2%, a
specificity of 67.7% and an AUC of 66.4% (95% CI 51.6e81.2).
Combining multiple parameters did not result in a higher
discriminative power.
Discussion
In this study, we attempted to detect FC in the buccal mucosa of lung
cancer patients. For this purpose we used MDSFR, which was
hypothesized to be sensitive to the sub-diffraction length tissue
changes caused by FC. Measurements were performed on oncologic
patients and matched controls. Several buccal mucosa optical
parameters showed significant differences between the lung cancer
and control groups.
Our primary interest lay in the comparison of the lung cancer and
COPD patients, since we hypothesized that the patients in these
groups would be as homogeneous as possible. Also COPD is closely
linked with lung cancer at a molecular level. [20] One notable result
of the present study is that the buccal mucosa StO2 was significantly
lower in the COPD patients, but not in the non-COPD control
group. However, this is probably not the result of FC but a
consequence of a systemic decrease in StO2 due to COPD. Therefore,
we believe that measuring the buccal mucosa StO2 for screening
purposes is not appropriate.
Interestingly, the scattering parameter ms' at 800 nm was also
near-significantly higher in the lung cancer group than the COPD
patients and significantly higher than in the, larger, non-COPD
group. An increase in ms' means that the photons that enter the
mucosa undergo more scattering events. This indicates that the buccal
mucosa of lung cancer patients has undergone some form of
transformation that might be the result of FC. [21] An increase of
scatter events is correlated with an increase of the local density of
macromolecules and changes in their organization. [22]P-value Non-COPD control P-value
(n ¼ 36)
.002* 75.9 (70.3e81.3) .553
.701 3.25 (2.73e3.61) .043*
.651 0.05 (0.04e0.06) .579
.060y 6.70 (4.70e8.39) .523
.072y 1.00 (0.93e1.05) .015*
.968 1.84 (1.69e2.06) .790
.058y 1.65 (1.60e1.71) .784
.585 1.68 (1.61e1.73) .064y
.157 1.67 (1.62e1.74) .880
¼ vessel diameter, [BIL]tis ¼ tissue bilirubin concentration, ms' ¼ reduced scattering coefficient,
easurement as a covariate. *P < .05, yP < .10.
Figure 2. ROC curves of blood oxygen saturation (solid line) and μs' at 800 nm (dashed lines) for predicting the presence of cancer
between the lung cancer and the two control groups. AUC ¼ area under the curve.
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design that used low-coherence enhanced backscattering spectroscopy
(LEBS). [13] The LEBS biomarker was also increased in lung cancer
patients, indicating buccal mucosa transformation due to FC.
However, the discriminative power of the LEBS power was higher
than ms' at 800 nm with a sensitivity, specificity, and AUC of 79%,
83%, 89%, respectively. It is unclear how this difference might be
explained. Two possible explanations are that their validation control
group consisted of 33% non-smokers and that Radosevich et al.
included 53% high-stage tumors (stage III and IV), compared to 30%
in the present study.
The discriminative power of our optical method was lower for
patients with lung cancer than for patients with head and neck or
esophageal squamous cell carcinoma, which we have investigated in
two earlier studies. [15,16] This might be explained by the distance
from the buccal mucosa to the tumor, which is the longest for lung
cancer. To our knowledge, there are no studies that investigated
optical methods to detect FC closer to the lung tumor (e.g., larynx,
trachea, or bronchi). However, this would increase the complexity of
the screening method, since it would require endoscopy.
There are some limitations of our study design that should be
considered. One is the relative small number of patients per group.
This might have led to an underestimation of the significance of the
differences between groups (p-value) and it prevented us from testing
the discriminative power of our optical parameters on an independent
training set. Another limitation is that the different groups were not
optimally matched. Age at measurement proved to be lower in both
control groups than the lung cancer group. However, we corrected for
this difference in our statistical analysis.
Conclusions
In conclusion, we have demonstrated that ms' at 800 nm is increased
in the buccal mucosa of patients with lung cancer compared to
controls with and without COPD. This increase could be anindication of FC in the oral cavity of patients with lung cancer. A
study with a larger study population is needed to investigate whether
MDSFR spectroscopy of the buccal mucosa could function as a (pre)
screening tool for lung cancer.
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